Key result
Transseptal valve-in-valve TMVR eliminated residual mitral regurgitation, reduced the mean transmitral gradient from 12 to 4.7 mmHg, and lowered sPAP from 80 to 25 mmHg at 3 months.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
This case report demonstrates that transseptal valve-in-valve transcatheter mitral valve replacement can successfully resolve severe bioprosthetic mitral regurgitation and pulmonary hypertension in a high-risk elderly patient.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Arachchilage et al. (2026) conducted a case report in Degenerated mitral valve bioprosthesis with severe intravalvular mitral regurgitation (n=1). Transseptal valve-in-valve transcatheter mitral valve replacement (26 mm Edwards Sapien 3 Ultra Resilia valve) was evaluated on Mean transmitral pressure gradient and systolic pulmonary artery pressure (sPAP). Transseptal valve-in-valve TMVR eliminated residual mitral regurgitation, reduced the mean transmitral gradient from 12 to 4.7 mmHg, and lowered sPAP from 80 to 25 mmHg at 3 months.
Synapse has enriched 10 related papers. Consider them for comparative context: